Synergistic effects of blood pressure-lowering drugs and statins: systematic review and meta-analysis

Johan Sundström, Gullik Gulliksson, Marcus Wirén

Abstract

Background Synergistic effects of blood pressure-lowering drugs and statins are unknown, but are key to risk-based treatment decision strategies and fixed-combination polypills.

Objective We conducted a systematic literature review and meta-analysis to test the hypothesis that the combined relative effects of blood pressure-lowering drugs and statins on cardiovascular outcomes are multiplicative.

Study selection Two persons independently searched five data sources and hand-searched reference lists from earliest available to December 2017. We included factorial trials with at least two randomised interventions including one statin versus placebo factor and one blood pressure-lowering drug/more intense blood pressure-lowering regimen versus placebo/less intense regimen factor, and reported cardiovascular events or mortality as outcomes. We tested interactions as departures from additivity or multiplicity using mixed-effects logistic regression models.

Findings Seven out of 1017 screened studies fulfilled the selection criteria, contributing a total of 27020 patients with 857 major cardiovascular events and 725 deaths. The relative risk reduction of major cardiovascular events with active more intense blood pressure-lowering regimen was not materially different in subgroups randomised to statins (risk ratio 0.81, 95% CI 0.66 to 1.00) or placebo (0.94, 0.79 to 1.11). Likewise, statin effects were not substantially different in subgroups randomised to active/more intense blood pressure-lowering regimen (0.69, 0.57 to 0.85) or placebo/less intense regimen (0.80, 0.67 to 0.96). No departures from either additivity or multiplicativity were observed. Heterogeneity was low.

Conclusions The combined relative effects of blood pressure-lowering drugs and statins on cardiovascular events were multiplicative. This supports risk-based treatment decision strategies and fixed-combination polypills.

Introduction

Cardiovascular diseases are the leading causes of death globally and are increasing.¹ Risk factors can be effectively treated, but more people need to be treated more aggressively for the high-risk strategy to be effective.² Proposed solutions include polypills³ and risk-based approaches⁴ ⁵, the latter recognising the merits of baring treatment decisions for the prevention of cardiovascular disease on a person’s predicted absolute risk of disease, rather than on the level of a single risk factor.⁶ ⁷ Both solutions need the answer to a specific, but hitherto overlooked question: are there any synergistic effects between the preventive drug treatments?

When a high-risk person is identified as a candidate for primary or secondary prevention against cardiovascular disease, the potential drug regimen is likely to include blood pressure-lowering drugs and statins. Combining these two treatments may result in anything from less than an additive effect to more than a multiplicative effect on cardiovascular disease risk. Experimental studies have suggested positive⁸ ⁹ as well as negative¹⁰ synergistic effects between blood pressure-lowering drugs and statins.

Several factorial trials with these two treatments have been made in humans, but as a whole, their interaction is unknown. With the recent addition to that literature,¹¹ the evidence base may now be sufficient to answer the question. We hypothesised that the combined effects of blood pressure-lowering and statins are multiplicative. In order to test the hypothesis, we performed a systematic review of randomised factorial trials of the effects of blood pressure-lowering drugs and statins on cardiovascular outcomes in primary or secondary prevention.

Methods

Data sources and searches

Using a pre-specified systematic review protocol, we performed data searches in MEDLINE, SCOPUS, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov, and Web of Knowledge conference abstracts, and limited the search from earliest available to December 2017. The MEDLINE search strategy was: (1) randomised controlled trial (pt); (2) controlled clinical trial (pt); (3) randomised (tiab); (4) clinical trial (all); (5) randomly (tiab); (6) trial (ti); (7) placebo (ti); (8) 1 or 2 or 3 or 4 or 5 or 6 or 7; (9) hypolipidaemic agents (mesh); (10) hydroxymethylglutaryl-CoA reductase inhibitors (mesh); (11) statin (tw); (12) 9 or 10 or 11; (13) antihypertensive agents (mesh); (14) cardiovascular (all); (15) cardiovascular diseases (majr); (16) 14 or 15; (17) 8 and 12 and 13 and 16. Similar search strategies were applied to the other sources. Reference lists of relevant publications were hand searched.

Study selection

Studies were included in the systematic review if they were factorial and had at least two randomised interventions, had a total duration...
of at least 100 patient-years, involved patients aged ≥18 years, had at least one statin and one blood pressure-lowering drug as active treatment, had placebo or a less intensive blood pressure-lowering drug regimen as control treatment, and reported clinical cardiovascular events or mortality as outcomes. Trials were excluded if they did not report clinical outcomes or if the intervention strategies were unclear. Due to scarcity of data, we included studies with different intensities of antihypertensive treatment in the blood pressure factor. We defined treatment groups in these studies as more versus less intensive.

**Table 1** Baseline characteristics

| Group              | Statin+BPRx | BPRx     | Placebo | Statin |
|--------------------|-------------|----------|---------|--------|
| Patients, n        | 7227        | 6539     | 6452    | 6802   |
| Age, years         | 63.2 (7.7)  | 63.7 (7.6)| 63.7 (7.6)| 63.6 (7.5) |
| Men, %             | 64.2        | 65.4     | 66.9    | 64.5   |
| BMI, kg/m²         | 27.7 (4.8)  | 27.7 (4.7)| 27.6 (4.6)| 27.7 (4.7) |
| Smoking, %         | 30.9        | 30.3     | 30.5    | 30.1   |
| Previous CVD, %    | 9.2         | 7.3      | 7.0     | 8.1    |
| Previous MI, %     | 1.3         | 1.4      | 1.3     | 1.4    |
| Type 2 diabetes, % | 14.3        | 14.4     | 14.0    | 14.2   |
| Hypertension, %    | 65.9        | 62.1     | 61.9    | 63.5   |
| SBP, mm Hg         | 148.3 (15.3)| 148.4 (16.1)| 147.8 (16.0)| 148.2 (15.9) |
| DBP, mm Hg         | 87.6 (9.2)  | 87.2 (9.6)| 87.0 (9.5)| 87.2 (9.5) |
| Hyperlipidaemia, % | 30.3        | 21.6     | 20.9    | 24.7   |
| LDL cholesterol, mM| 3.57 (0.85) | 3.46 (0.84)| 3.44 (0.84)| 3.51 (0.83) |
| HDL cholesterol, mM| 1.22 (0.36) | 1.22 (0.35)| 1.22 (0.36)| 1.22 (0.35) |

BMI, body mass index; BPRx, blood pressure-lowering treatment; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; SBP, systolic blood pressure.
Evidence synthesis: Primary care

antihypertensive treatment based on achieved blood-pressure differences on the group level. In case of several useful publications from the same study, the one with the longest duration of follow-up was used. Two independent reviewers screened all abstracts for eligibility, reviewed relevant articles in full text, included relevant articles in the systematic review and, if applicable, extracted data for the meta-analysis.

Data extraction and bias assessments
Data were extracted from the articles using a prespecified spreadsheet. In case of unclear reporting of results, we contacted the authors asking for supplementary information. Data items extracted included study identification variables, treatments, numbers of patients, age, sex, baseline variables (body mass index, smoking, known hypertension, known dyslipidaemia, previous cardiovascular disease, previous myocardial infarction, type 2 diabetes, systolic and diastolic blood pressures, total, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol; described in the online supplementary table 1) and outcome variables (major adverse cardiovascular events (MACE, as defined by the studies, mainly including myocardial infarction, stroke and cardiovascular death, optionally also heart failure), MACE-plus (expanded MACE classifications, as defined by the studies, usually adding unstable angina and coronary revascularisation), myocardial infarction, stroke, cardiovascular death, and total death; described in the online supplementary table 2). Quality of the included trials was gauged by using the Cochrane Collaboration’s risk-of-bias tool. Publication bias was assessed using funnel plots and Egger’s tests.

Data synthesis and analysis
Baseline data were summarised using inverse variance weights. Treatment effects were visualised in forest plots of tabular trial data, using fixed-effects inverse variance-weighted meta-analysis models to illustrate heterogeneity as the I² statistic.

In order to investigate synergistic effects, we used a one-step individual patient data meta-analysis approach\(^\text{12}\) with a two-level mixed-effects logistic regression model with patient as the unit of analysis and trial modelled on a second level with random intercept. Models with the addition of random coefficients for treatments did not have a better fit than models with only a random

Figure 2 Effects of blood pressure-lowering treatment by subgroups of statin treatment. BPRx, blood pressure-lowering treatment; MACE, major adverse cardiovascular events; RR, risk ratio.
Evidence synthesis: Primary care

Because the aggregate data used in this study are all dichotomous variables, a complete representation of the individual participant data for the primary analyses could be achieved.14 Because there is no generally accepted statistical definition of pharmacological synergism, we tested for interactions in two ways: as departure from additivity and as departure from multiplicativity. Departure from additivity was investigated as the relative excess risk due to interaction (RERI), the attributable proportion due to interaction (AP) and as the synergy index (S),15 in the mixed-effects models described above. In the absence of interaction on the additive scale, RERI and AP are equal to 0 and S is equal to 1. Departure from multiplicativity was examined using a within-trial product of the variables for statins and blood pressure-lowering drugs, added to the otherwise same mixed-effects models. In the absence of interaction on the multiplicative scale, the OR for that product is equal to 1.

We used two-sided 95% CIs for all hypothesis tests. Stata V.14.2 was used for all analyses.

**Patient involvement**

No patients were involved in the design, conduction, interpretation or reporting of the analyses.

**Results**

Out of 1017 studies screened, 39 were read in full text and 71116–21 were eventually included in the overview (figure 1). Using funnel plots (online supplementary figure 1), no evidence of publication bias was observed (all Egger’s test P>0.12). Risk of bias within studies was generally low (online supplementary figures 1 and 2).

The included trials contributed a total of 27020 patients. Baseline characteristics are described by the study group in table 1, and by trial in the online supplementary table 1. The trials were heterogeneous in terms of target populations, with some recruiting from the general population and some only among patients with established cardiovascular disease or organ damage. Baseline characteristics were well balanced between the randomised groups.

The trials contributed 1560 MACE-plus events, 857 MACE events, 409 strokes, 144 myocardial infarctions, 725 deaths and

---

**Figure 3** Effects of statin treatment by subgroups of blood pressure-lowering treatment. BPRx, blood pressure-lowering treatment; MACE, major adverse cardiovascular events; RR, risk ratio.
348 cardiovascular deaths. Relative risk reductions with blood pressure-lowering drugs/more intense blood pressure-lowering regimen and statins are presented per trial in the online supplementary figure 4.

The relative risk reduction with blood pressure-lowering drugs/more intense blood pressure-lowering regimen was not materially different in subgroups randomised to blood pressure-lowering drugs/more intense blood pressure-lowering regimen or placebo/less intense regimen (figure 2). Likewise, the relative risk reduction with statins was not substantially different in subgroups randomised to blood pressure-lowering drugs/more intense blood pressure-lowering regimen or placebo/less intense regimen (figure 2).

Interaction analyses did not reveal any departures from either additivity or multiplicativity (table 2). The analysis cannot exclude the possibility of a small synergistic effect between the randomised treatments on major cardiovascular events, but it is not statistically significant given the current evidence base.

Heterogeneity was low overall; hence, subgroup analyses were not called for. Results were largely driven by findings in two large trials (online supplementary figure 4).

Discussion
In this systematic review of randomised factorial trials, the joint relative effects of blood pressure-lowering drugs and statins on major cardiovascular events appeared multiplicative. The analysis cannot exclude the possibility of a slightly more than multiplicative effect between the treatments on major cardiovascular events, but it is unlikely that the combined effect is less than multiplicative.

There is some experimental evidence regarding pharmacological synergism between blood pressure-lowering drugs and statins, with a few studies proposing potentiating synergistic effects and one suggesting diminished combined effects. In humans, observations in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) supported synergistic effects, but the recent Heart Outcomes Prevention Evaluation-3 (HOPE-3) study did not. While differences between the two studies may be explained by the different drug regimens (candesartan/hydrochlorothiazide vs placebo and rosuvastatin vs placebo in HOPE-3 and amlodipine/perindopril vs atenolol/bendroflumethiazide and atorvastatin vs placebo in ASCOT) or different populations (higher risk sample in ASCOT with markedly higher blood pressure), they may also be due to chance (the full-factorial combinations underpowered compared with the primary comparisons in the original studies). With the latest addition to the evidence base, we assumed it large enough now to answer the question.

The question is of substantial clinical importance. With the increasing recognition of similar relative effects of statins and blood pressure-lowering drugs across the whole spectra of cholesterol and blood pressure, and consequent merits of risk-based treatment decisions, the clinician needs to know how to treat a patient identified to be at high risk. Any potentiating synergistic effects should steer the treatment choice towards introducing both statins and blood pressure-lowering drugs in high-risk people in primary prevention, irrespectively of cholesterol and blood pressure levels. Likewise, any potentiating synergistic effects should also argue for fixed-combination polypills.

### Table 2 Departures from additivity and multiplicativity of effects

| Outcome                  | Departure from additivity | Departure from multiplicativity |
|--------------------------|---------------------------|---------------------------------|
|                          | Numbers | Measure | Estimate | Lower | Upper | Factor | OR     | Lower | Upper |
| MACE-plus                | N trials 3 | RERI   | −0.04   | −0.22 | 0.14 | Statin | 0.80   | 0.69 | 0.92 |
|                         | N persons 23 874 | AP    | −0.06   | −0.32 | 0.20 | BPRx   | 0.92   | 0.80 | 1.05 |
|                         | N events 1 560 | S     | 1.14    | 0.61 | 2.12 | Statin + BPRx | 0.92 | 0.75 | 1.14 |
| MACE                     | N trials 5 | RERI   | −0.09   | −0.32 | 0.15 | Statin | 0.79   | 0.66 | 0.96 |
|                         | N persons 24 496 | AP    | −0.14   | −0.51 | 0.23 | BPRx   | 0.93   | 0.77 | 1.11 |
|                         | N events 8 57 | S     | 1.31    | 0.56 | 3.05 | Statin + BPRx | 0.86 | 0.65 | 1.13 |
| Stroke                   | N trials 5 | RERI   | 0.02    | −0.26 | 0.31 | Statin | 0.76   | 0.59 | 0.98 |
|                         | N persons 25 127 | AP    | 0.05    | −0.55 | 0.65 | BPRx   | 0.70   | 0.54 | 0.90 |
|                         | N events 4 09 | S     | 0.96    | 0.57 | 1.61 | Statin + BPRx | 0.90 | 0.60 | 1.35 |
| Myocardial infarction    | N trials 3 | RERI   | 0.18    | −0.28 | 0.64 | Statin | 0.66   | 0.42 | 1.03 |
|                         | N persons 13 958 | AP    | 0.31    | −0.49 | 1.11 | BPRx   | 0.74   | 0.48 | 1.15 |
|                         | N events 1 44 | S     | 0.70    | 0.31 | 1.56 | Statin + BPRx | 1.19 | 0.61 | 2.32 |
| Death                    | N trials 5 | RERI   | −0.04   | −0.33 | 0.25 | Statin | 0.97   | 0.79 | 1.19 |
|                         | N persons 15 851 | AP    | −0.04   | −0.36 | 0.28 | BPRx   | 0.97   | 0.79 | 1.20 |
|                         | N events 7 25 | S     | 1.63    | 0.01 | 290.53 | Statin + BPRx | 0.96 | 0.71 | 1.30 |
| Cardiovascular death     | N trials 5 | RERI   | 0.13    | −0.23 | 0.49 | Statin | 0.85   | 0.63 | 1.14 |
|                         | N persons 15 055 | AP    | 0.16    | −0.28 | 0.59 | BPRx   | 0.85   | 0.63 | 1.14 |
|                         | N events 3 48 | S     | 0.57    | 0.14 | 2.27 | Statin + BPRx | 1.15 | 0.75 | 1.76 |

AP, attributable proportion due to interaction; BPRx, blood pressure-lowering treatment; Lower, lower 95% CI limit; MACE, major adverse cardiovascular events; N, number; RERI, relative excess risk due to interaction; S, synergy index; Upper, upper 95% CI limit.
of at least the anticipated relative risk reductions of each of the treatments. Weaknesses of this study include the low power for analyses of some outcomes and heterogeneous treatment regimens in the included studies, which on the other hand all are representatives of drug classes available to answer the research question. Further, heterogeneity in results was fairly low in spite of the different treatments. Strengths of this study include the large sample relevant for prevention situations in primary care, stringent systematic review methods including transparent analysis of several biases, and analyses of interaction on both the additive and multiplicative scales. It should be noted that definitions and analytical operationalisations of synergy are debated. Using analogies to pharmacological analyses of drug combinations, the analyses of the present study reflect effect-based rather than dose–effect–based strategies, and most closely reflect the Bliss Independence model. Synergy can be assessed as departure from additivity on an absolute risk scale, and as departure from multiplicativity on a relative risk scale. A strength of the analysis framework in this study is that incorporates both analyses.

In sum, the combined relative effects of blood pressure-lowering drugs and statins on major cardiovascular events were multiplicative in this systematic review of factorial trials. The possibility of a slightly more than multiplicative effect between the treatments could not be excluded and future factorial trials may add relevant evidence.

Contributors MW performed literature review, collected the data, interpreted the data and contributed to the writing of the article. GG performed literature review, collected the data and interpreted the data. JS designed the study, handled funding, supervision, statistical analysis, interpreted the data and wrote the article. JS had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Competing interests JS reports being on the advisory board for Itrim, outside of the study. GG and MW report no competing interests.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to use is permitted unless otherwise expressly granted.

References
1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–128.
2. Emberson J, Whincup P, Morris R, et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004;25:484–91.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2001;326:1419–25.
4. Sundström J, Neal B. Replacing the hypertension control paradigm with a strategy of cardiovascular risk reduction. European Heart J – Quality of Care and Clinical Outcomes 2015;1:17–22.
5. Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1991;307:107–10.
6. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581–90.
7. Sundström J, Arima H, Woodward M, et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014;384:591–8.
8. Abdel-Zaheer AO, Elkoussi AE, Abudabah LH, et al. Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein. Fundam Clin Pharmacol 2014;28:237–48.
9. Munro E, Patel M, Chan P, et al. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 1994;24:766–72.
10. Bayrth MA, Ganafa AA, Etemad D, et al. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens 2005;18:1496–502.
11. Yusuf S, Lonn E, Pais P, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016;374:2032–43.
12. Riley RD, Lambert PC, Staessen JA, et al. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med 2008;27:1870–93.
13. Fisher DJ, Copas AJ, Tierney JF, et al. A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. J Clin Epidemiol 2011;64:549–67.
14. Riley RD, Steyerberg EW. Meta-analysis of a binary outcome using individual participant data and aggregate data. Res Synth Methods 2010;1:2–19.
15. Andersson T, Alfredsson L, Källberg H, et al. Calculating measures of biological interaction. Eur J Epidemiol 2005;20:575–9.
16. Asselbergs FW, Diercks GF, Hilleghe HL, et al. Prevention of R and Vascular Endstage Disease Intervention Trial I. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809–16.
17. Hedblad B, Wikstrand J, Janson L, et al. Low-dose metoprolol cr/xl and fluvastatin slow progression of carotid intima-media thickness: main results from the -Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001;103:1721–6.
18. ENCORE Investigators. Effect of nifedipine and carvedilol on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Carvedilol On Recovery of Coronary Endothelial function). Circulation 2003;107:412–8.
19. Preston RA, Harvey P, Herfort O, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlopidine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the resop trial. J Clin Pharmacol 2007;47:1555–69.
20. Sever P, Dahlöf B, Poulier N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006;27:2982–8.
21. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial [SCAT]. Circulation 2000;102:1748–54.
22. Fouquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 2015;3:e00149.